### A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): An Introduction

Amy Place, PhD, MBA, MS, RD, CLT Global Medical Affairs Scholar Rock, Inc.

Cure SMA June 12th, 2020

# Disclaimer


• SRK-015 is an investigational product candidate that is currently being evaluated in a clinical trial

• SRK-015 has not been approved by the U.S. Food and Drug Administration (FDA), the European Commission, or any other health authority, and the safety and effectiveness of this molecule have not been established

# Disclosures

• Amy Place is an employee of Scholar Rock and owns equity in the company.

### **TOPAZ Study Schematic: Treatment Period**




## SRK-015 Phase 2 Trial (TOPAZ): Objectives and Design

	Cohort 1	Cohort 2	Cohort 3		
Design	<ul> <li>N= 20; ages 5-21</li> <li>Open-label, single-arm</li> <li>20 mg/kg SRK-015 IV Q4W</li> <li>12-month treatment period</li> </ul>	<ul> <li>N= 15; ages 5-21</li> <li>Open-label, single-arm</li> <li>20 mg/kg SRK-015 IV Q4W</li> <li>12-month treatment period</li> </ul>	<ul> <li>N= 20; ages ≥2</li> <li>Double-blind, randomized (1:1) to 2 mg/kg or 20 mg/kg SRK-015 IV Q4W</li> <li>12-month treatment period</li> </ul>		
Patients	<ul> <li>Ambulatory Type 3 SMA</li> <li>Receiving treatment with approved SMN upregulator or as monotherapy</li> </ul>	<ul> <li>Type 2 or non-ambulatory Type 3 SMA</li> <li>Receiving treatment with approved SMN upregulator</li> </ul>	<ul> <li>Type 2 SMA</li> <li>Initiated treatment with approved SMN upregulator before age 5</li> </ul>		
Primary ojectives	<ul><li>Safety</li><li>Mean change from baseline in RHS</li></ul>	<ul> <li>Safety</li> <li>Mean change from baseline in HFMSE</li> </ul>	<ul> <li>Safety</li> <li>Mean change from baseline in HFMSE</li> </ul>		

RHS: Revised Hammersmith Scale HFMSE: Hammersmith Functional Motor Scale Expanded

Ob

### **TOPAZ Study Schematic: Extension Period**





## Study Participant Baseline Demographics (1/2)


Age (Years) at Informed Consent by Cohort							Age (Years) at Diagnosis by Cohort				
Cohort	Ν	Mean	Std	Min	Med	Max	15 _		0		
1	23	12.6	4.53	7	13.0	21		о			
2	15	11.7	3.94	8	10.0	19	Age at Diagnosis	0	0		
3	20	4.0	1.23	2	4.0	6	5 _		0	0 00	
Total	58	9.4	5.31	2	8.0	21	o	1	cococo 2 Cohort	3	

Scholar Rock. Data on File. March 2020


## Study Participant Baseline Demographics (2/2)











<sup>†</sup>Excluded Cohort 1 patients who are not on Nusinersen

#### Scholar Rock. Data on File. March 2020

### **Study Participant Baseline Motor Function**

Cohort 1: RHS* Score at Screening									
N		Mean	Std	Min	Med	Max			
RHS Score	23	49.0	11.00	25	49	63			

Cohort 1: 6 Minute Walk at Screening <sup>‡</sup>								
	Ν	Mean	Std	Min	Med	Max		
Distance Walked (m)	20	260.1	166.85	11	341.0	514		

Cohorts 2 and 3: HFMSE** at Screening								
Cohort	Ν	Mean	Std	Min	Med	Max		
2	15	22.3	8.98	12	19.0	37		
3	19	25.0	9.58	12	22.0	44		
Total	34	23.8	9.28	12	21.5	44		


\*Top RHS score 69 points

\*\*Top HFMSE score 66 points

**‡** Only including patients who are ambulatory and completed the test

RHS: Revised Hammersmith Scale HFMSE: Hammersmith Functional Motor Scale Expanded

### Preliminary TOPAZ Biomarker Data Provide First Demonstration of Target Engagement in SMA



Time (hr)

### Well-Behaved, Linear PK Profile

- Minimal variability across cohorts
- Dose proportional increase in serum drug exposure between low (2 mg/kg) and high (20 mg/kg) doses

### **Robust Target Engagement Observed**

- ~100-fold increase in serum latent myostatin levels following single 20 mg/kg dose in all cohorts
- Confirms presence of latent myostatin in patients with SMA

Preliminary PK/PD results from planned data cutoff in November 2019 include data from 29 patients (12 in Cohort 1, 8 in Cohort 2, and 9 in Cohort 3). Press release announcing preliminary PK/PD data (Nov 19, 2019) at www.scholarrock.com.

### SRK-015 Phase 2 Trial (TOPAZ) Timelines

- All 3 cohorts fully enrolled
- Interim analysis: 6-month treatment period
- Top-line results: 12-month treatment period
- Patients eligible to continue treatment for an additional 12-month extension period
- Results from TOPAZ trial may inform future studies in SMA

SRK-015 has the potential to be the first muscle-directed therapy for patients with SMA

# Acknowledgements

- Phase 2 trial study investigators, site staff and participants
- Medpace
- Internal team Members:
  - Yung Chyung
  - Ryan larrobino
  - Doreen Barrett
  - Amy Place
  - Tiina Xu
  - Stephanie D'Eon
  - Mara Sadanowicz
  - Heather Faulds
  - Erin Treece
  - Shaun Cote
  - Ashish Kalra
  - Kimberly Long
  - Deborah Meshulam
  - Ann Price
  - Mania Kavosi
  - Ping Huang